Diabetes, metforminuse,andcolon cancer: A population-based cohort study in Taiwan

European Journal of Endocrinology

Volumn 167, Issue 3, 2012, Pages 409-416

  Tseng, Chin Hsiao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COLON CANCER; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TAIWAN; TREATMENT DURATION; AGED; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH SURVEY; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84865717087     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0369     Document Type: Article

References (28)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL & Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010 116 544-573. (doi:10.1002/cncr.24760)
2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P & Levi F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology 2010 21 1323-1360. (doi:10.1093/annonc/mdp530)
3. Hyodo I, Suzuki H, Takahashi K, Saito Y, Tanaka S, Chiu HM, Kim NK, Li J, Lim R, Villalon A & Boku N. Present status and perspectives of colorectal cancer in Asia: Colorectal Cancer Working Group report in 30th Asia-Pacific Cancer Conference. Japanese Journal of Clinical Oncology 2010 40 (Suppl 1) i38-i43. (doi:10.1093/jjco/hyq125)
4. Bureau of Health Promotion. Cancer Registry Annual Report, 2008, Taiwan. http://www1.cgmh.org.tw/lhcc/file/01.news/1000413ca.pdf (accessed 22 April 2011).
5. Giouleme O, Diamantidis MD & Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World Journal of Gastroenterology 2011 17 444-448. (doi:10.3748/wjg.v17.i4.444)
6. Larsson SC, Orsini N & Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute 2005 97 1679-1687. (doi:10.1093/jnci/dji375)
7. Giovannucci E & Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007 132 2208-2225. (doi:10.1053/j.gastro.2007.03.050)
8. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010 33 1674-1685. (doi:10.2337/dc10-0666)
9. Tseng CH, Chong CK, Tseng CP & Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. Annals of Medicine 2009 41 371-379. (doi:10.1080/ 07853890902729778)
10. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011 54 2009-2015. (doi:10.1007/s00125-011-2171-z)
11. Tseng CH, Chong CK & Tai TY. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia 2009 52 240-246. (doi:10.1007/s00125-008-1204-8)
12. Yang YX, Hennessy S & Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004 127 1044-1050. (doi:10.1053/j.gastro.2004.07.011)
13. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW & Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009 52 1732-1744. (doi:10.1007/s00125-009-1418-4)
14. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S & Steineck G. Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia 2009 52 1745-1754. (doi:10.1007/s00125-009-1444-2)
15. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH & Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011 11 20. (doi:10.1186/1471-2407-11- 20)
16. Currie CJ, Poole CD & Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 52 1766-1777. (doi:10.1007/s00125-009-1440-6)
17. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD & Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009 32 1620-1625. (doi:10.2337/dc08-2175)
18. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO & Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010 33 322-326. (doi:10.2337/dc09-1380)
19. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G & Kip KE. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011 34 2323-2328. (doi:10.2337/dc11- 0512)
20. Okumura T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. Journal of Gastroenterology 2010 45 1097-1102. (doi:10.1007/s00535-010-0310-9)
21. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B & Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 2010 3 1451-1461. (doi:10.1158/1940-6207.CAPR-10-0157)
22. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H & Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Research 2010 3 1077-1083. (doi:10.1158/1940-6207.CAPR-10-0186)
23. Kourelis TV & Siegel RD. Metformin and cancer: new applications for an old drug. Medical Oncology 2012 29 1314-1327. (doi:10.1007/s12032-011-9846-7)
24. Guppy A, Jamal-Hanjani M & Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncology 2011 7 727-736. (doi:10.2217/fon.11.49)
25. Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP Jr & Habel LA. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiology and Drug Safety 2007 16 1195-1202. (doi:10.1002/pds.1441)
26. Tseng CH. New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas 2012 In press. (doi:10.1097/MPA.0b013e3182571ba9)
27. McCormack VA & Boffetta P. Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Annals of Oncology 2011 22 2349-2357. (doi:10.1093/annonc/mdq763)
28. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD & Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prevention Research 2010 3 1066-1076. (doi:10.1158/1940-6207.CAPR-10-0055)